Sarah Krepp Biography and Net Worth

Insider of Liquidia

Sarah Krepp joined Liquidia in 2023 where she serves as Chief Human Resources Officer. She brings more than 19 years of experience in consulting, start-ups, mid-sized pharmaceuticals, and large clinical research organizations to her role at Liquidia. Previously, Sarah held progressive HR leadership roles at PRA, Salix, Chimerix, Istari Oncology, and most recently as Head of People and Culture for Fujifilm Diosynth Biotechnologies. She began her career working in the genetics laboratory for Bayer (later Talecris), before transitioning into the field of human resources. Sarah holds a Bachelor of Science in Biology from North Carolina State University and has specialized training in Executive Compensation and Organizational Psychology.

What is Sarah Krepp's net worth?: The estimated net worth of Sarah Krepp is at least $4.79 million as of December 1st, 2025. Krepp owns 141,218 shares of Liquidia stock worth more than $4,790,115 as of December 4th. This net worth approximation does not reflect any other investments that Krepp may own. Learn More about Sarah Krepp's net worth.
How do I contact Sarah Krepp?: The corporate mailing address for Krepp and other Liquidia executives is 419 DAVIS DRIVE SUITE 100, MORRISVILLE NC, 27560. Liquidia can also be reached via phone at (919) 328-4400 and via email at [email protected]. Learn More on Sarah Krepp's contact information.
Has Sarah Krepp been buying or selling shares of Liquidia?: Within the last three months, Sarah Krepp has sold $46,700.30 in Liquidia stock. Most recently, Sarah Krepp sold 221 shares of the business's stock in a transaction on Monday, December 1st. The shares were sold at an average price of $32.19, for a transaction totalling $7,113.99. Following the completion of the sale, the insider now directly owns 141,218 shares of the company's stock, valued at $4,545,807.42. Learn More on Sarah Krepp's trading history.
Who are Liquidia's active insiders?: Liquidia's insider roster includes Jason Adair (Chief Business Officer), Dana Boyle (CAO), Roger Jeffs (CEO), Michael Kaseta (CFO), Arthur Kirsch (Director), Sarah Krepp (Insider), Paul Manning (Director), Scott Moomaw (Chief Commercial Officer), Rajeev Saggar (Insider), Russell Schundler (General Counsel), and Raman Singh (Director). Learn More on Liquidia's active insiders.
Are insiders buying or selling shares of Liquidia?: In the last year, insiders at the sold shares 52 times. They sold a total of 1,155,124 shares worth more than $29,483,872.80. The most recent insider tranaction occured on December, 1st when General Counsel Russell Schundler sold 1,072 shares worth more than $34,507.68. Insiders at Liquidia own 26.5% of the company. Learn More about insider trades at Liquidia.
Information on this page was last updated on 12/1/2025.

Sarah Krepp Insider Trading History at Liquidia

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/1/2025	Sell	221	$32.19	$7,113.99	141,218
10/13/2025	Sell	1,691	$23.41	$39,586.31	141,439
7/14/2025	Sell	2,673	$14.28	$38,170.44	142,499

Sarah Krepp Buying and Selling Activity at Liquidia

Liquidia Company Overview

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion. The company also a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.

Today's Range

Now: $33.92

$33.00

$34.08

50 Day Range

MA: $26.04

$21.80

$33.92

2 Week Range

Now: $33.92

$10.37

$34.08

Volume

880,832 shs

Average Volume

1,935,568 shs

Market Capitalization

$2.95 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.48